Key result
Dexmedetomidine significantly reduced plasma cortisol, epinephrine, norepinephrine, and serotonin elevations compared to saline in patients undergoing cardiac valve replacement.
Why the study?
Stress responses consistently occur in patients undergoing cardiac valve replacement with cardiopulmonary bypass.
Does intravenous dexmedetomidine reduce plasma stress hormone levels and improve recovery times in patients undergoing cardiac valve replacement with cardiopulmonary bypass?
RCT (n=60)
Double-blind
Randomized
No
Does intravenous dexmedetomidine reduce plasma stress hormone levels and improve recovery times in patients undergoing cardiac valve replacement with cardiopulmonary bypass?
p-value: p=<0.05
Intravenous dexmedetomidine significantly attenuates the neuroendocrine stress response and shortens ICU and ventilator times in patients undergoing cardiac valve replacement.
No takes yet. Share an insight, caveat, or question.
Attenuates stress response in cardiac valve replacement; extends RCT evidence for dexmedetomidine and supports outcome trials.
Wu et al. (2020) conducted an RCT in Cardiac valve replacement undergoing cardiopulmonary bypass (n=60). Dexmedetomidine vs. Normal saline was evaluated on Plasma cortisol, epinephrine, norepinephrine, and serotonin levels at 24 hours post-operation (T3) (p=<0.05). Dexmedetomidine significantly reduced plasma cortisol, epinephrine, norepinephrine, and serotonin elevations compared to saline in patients undergoing cardiac valve replacement.